Evidence map›Paper›PMID 40220218›Full record

ArticleObesity surgery2025

Bariatric Surgery and Risk of End-Stage Liver Disease in a Four-Country Cohort Study.

Dag Holmberg, Giola Santoni, My von Euler-Chelpin, Joonas H Kauppila, Eivind Ness-Jensen, Jesper Lagergren

Abstract read
In one paragraph

Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dag HolmbergDepartment of Molecular Medicine and Surgery, Karolinska Institute, and Karolinska University Hospital, Stockholm, Sweden. dag.holmberg@ki.se.
Giola SantoniDepartment of Molecular Medicine and Surgery, Karolinska Institute, and Karolinska University Hospital, Stockholm, Sweden.
My von Euler-ChelpinDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark.
Joonas H KauppilaDepartment of Molecular Medicine and Surgery, Karolinska Institute, and Karolinska University Hospital, Stockholm, Sweden.
Eivind Ness-JensenDepartment of Molecular Medicine and Surgery, Karolinska Institute, and Karolinska University Hospital, Stockholm, Sweden.
Jesper LagergrenDepartment of Molecular Medicine and Surgery, Karolinska Institute, and Karolinska University Hospital, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease can progress to end-stage liver disease. Whether bariatric surgery influences this risk is uncertain.

methodsThis population-based cohort study included all patients with an obesity diagnosis between 1989 and 2020 according to the nationwide patient registries in Denmark, Finland, Norway, and Sweden. Bariatric surgery was compared with non-operative care for incidence and mortality in end-stage liver disease. Patients with a history of alcohol overconsumption or liver disease at baseline were excluded. Multivariable Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for sex, calendar year, diabetes, Charlson comorbidity index, and country.

resultsAmong 654,409 participants with obesity, 86,356 (12.6%) underwent bariatric surgery. During a follow-up period of up to 31 years (median 7.3 years), bariatric surgery was followed by increased incidence (HR 1.23, 95% CI 1.11-1.37) and mortality (HR 1.93, 95% CI 1.56-2.38) in end-stage liver disease compared to non-operative care. The incidence decreased between 1 and 5 years after bariatric surgery but thereafter increased. Censoring patients who developed specific liver diseases (not steatotic liver disease) or alcohol overconsumption during follow-up canceled the association (HR 0.92, 95% CI 0.70-1.06). The mortality in end-stage liver disease was similar after bariatric surgery compared to non-operative care within 1-5 years of follow-up, but thereafter more than twofold increased. Analyses restricted to gastric bypass showed similar associations regarding both incidence (HR 1.26, 95% CI 1.11-1.43) and mortality (HR 2.20, 95% CI 1.72-2.82) of end-stage liver disease.

conclusionBariatric surgery might be followed by an increased risk of end-stage liver disease.

Indexed as

Bariatric SurgeryEnd Stage Liver DiseaseObesity, MorbidAdultCohort StudiesDenmarkFemaleFinlandFollow-Up StudiesHumansIncidenceMaleMiddle AgedRegistriesRisk FactorsSwedenCirrhosisMASLDMetabolic syndromeObesityWeight loss

Identifiers

PMID40220218
PMCPMC12065758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.